NCT02893254View on ClinicalTrials.gov

Efficacy and Safety of IBI303 in Adult Patients With Active Ankylosing Spondylitis

PHASE3CompletedINTERVENTIONAL
Enrollment

438

Participants

Timeline

Start Date

September 22, 2016

Primary Completion Date

January 22, 2018

Study Completion Date

March 16, 2018

Conditions
AS
Interventions
DRUG

IBI303

12 cycles. IBI303: 40 mg, iH

DRUG

Adalimumab

12 cycles. Adalimumab: 40mg, iH

All Listed Sponsors
lead

Innovent Biologics (Suzhou) Co. Ltd.

INDUSTRY

NCT02893254 - Efficacy and Safety of IBI303 in Adult Patients With Active Ankylosing Spondylitis | Biotech Hunter | Biotech Hunter